Stryker Corporation $SYK Shares Sold by Focus Partners Advisor Solutions LLC

Key Points

• Focus Partners Advisor Solutions cut its Stryker stake by 12.4% in the second quarter, selling 8,950 shares and retaining 63,079 shares valued at approximately $19.86 million. Institutional investors and hedge funds collectively own 77.09% of Stryker.
• Analysts maintain a broadly positive outlook, with one Strong Buy, 17 Buy and six Hold ratings; the stock has an average “Moderate Buy” rating and a consensus price target of $386.28.
• Stryker exceeded quarterly earnings expectations, reporting $3.69 in EPS and $6.59 billion in revenue, while revenue grew 9.4% year over year. The company also declared a quarterly dividend of $0.88 per share, implying a 1.0% yield.

Focus Partners Advisor Solutions LLC reduced its holdings in Stryker Corporation (NYSE:SYK - Free Report) by 12.4% during the second quarter, according to the company in its most recent filing with the SEC. The fund owned 63,079 shares of the medical technology company's stock after selling 8,950 shares during the quarter. Focus Partners Advisor Solutions LLC's holdings in Stryker were worth $19,860,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also modified their holdings of the business. Sankala Group LLC acquired a new stake in Stryker during the fourth quarter worth about $26,000. Godfrey Financial Associates Inc. bought a new position in Stryker in the fourth quarter worth about $26,000. United Financial Planning Group LLC acquired a new position in Stryker in the third quarter valued at approximately $27,000. Atlas Capital Advisors Inc. acquired a new position in Stryker in the fourth quarter valued at approximately $27,000. Finally, DJE Kapital AG bought a new position in shares of Stryker during the fourth quarter valued at approximately $28,000. 77.09% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts have recently weighed in on the company. Needham & Company LLC dropped their price target on Stryker from $454.00 to $418.00 and set a "buy" rating on the stock in a research report on Friday, May 1st. Robert W. Baird set a $385.00 price objective on Stryker in a research report on Friday, May 1st. Wells Fargo & Company lowered their price objective on Stryker from $456.00 to $418.00 and set an "overweight" rating for the company in a research note on Friday, May 1st. BTIG Research dropped their target price on Stryker from $371.00 to $358.00 and set a "buy" rating on the stock in a research report on Friday, July 31st. Finally, Sanford C. Bernstein set a $410.00 target price on Stryker in a research note on Friday, May 1st. One investment analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have assigned a Hold rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $386.28.

Stryker Price Performance

Shares of NYSE:SYK opened at $338.80 on Monday. The firm's 50 day moving average is $324.61 and its two-hundred day moving average is $333.40. Stryker Corporation has a 52 week low of $281.00 and a 52 week high of $396.86. The firm has a market capitalization of $129.95 billion, a P/E ratio of 35.11, a PEG ratio of 2.16 and a beta of 0.76. The company has a current ratio of 2.16, a quick ratio of 1.33 and a debt-to-equity ratio of 0.59.

Stryker (NYSE:SYK - Get Free Report) last released its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share for the quarter, beating analysts' consensus estimates of $3.49 by $0.20. The company had revenue of $6.59 billion for the quarter, compared to analysts' expectations of $6.58 billion. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The business's revenue for the quarter was up 9.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $3.13 earnings per share. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Analysts anticipate that Stryker Corporation will post 15.02 earnings per share for the current year.

Stryker Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be paid a dividend of $0.88 per share. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $3.52 annualized dividend and a yield of 1.0%. Stryker's payout ratio is presently 36.48%.

Insiders Place Their Bets

In other news, VP Robert S. Fletcher sold 4,544 shares of the stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $306.87, for a total value of $1,394,417.28. Following the completion of the transaction, the vice president owned 10,582 shares of the company's stock, valued at approximately $3,247,298.34. This represents a 30.04% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Ronda E. Stryker sold 310,000 shares of the stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $312.23, for a total value of $96,791,300.00. Following the completion of the transaction, the director directly owned 1,924,880 shares of the company's stock, valued at approximately $601,005,282.40. The trade was a 13.87% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 4.60% of the company's stock.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons' offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source